TABLE 1
FROM:
Biogenerics 2007: How far have we come?
John Tucker, Seth Yakatan and Stan Yakatan
BACK TO ARTICLETable 1. Follow-on biopharmaceutical market opportunities*
| Therapeutic class | 2006 Worldwide sales | Therapeutic area | Key market challenges |
|---|---|---|---|
| Erythropoietins | $12bn | Cancer and haemodialysis-associated anaemia | Competition from Aranesp (darbopoetin alfa), a second-generation erythropoietin that has more convenient dosing, 33% (and growing) market share, and significant remaining patent life |
| Insulin and insulin analogs | $9bn | Diabetes | Highly fragmented market. Multiple brands with high recognition, multiple insulin analogs with improved properties, and significant remaining patent life |
Interferon- | $4.4bn | Multiple sclerosis | Potential for increasing competition from other treatment modalities |
| G-CSF | $4.4bn | Cancer chemotherapy-associated neutropenia | Competition from Neulasta (pegfilgrastim), a second-generation G-CSF that has more convenient dosing, 51% (and growing) market share, and significant remaining patent life |
| Human growth hormone | $2.5bn | Growth hormone deficiency | Significant innovator investment in the development of convenient dosing devices |
Interferon-
| $2.3bn | Viral hepatitis, certain cancers | Competition from second generation products that have more convenient dosing, 70% market share, and significant remaining patent life |
* Data from References1, 20